MeiraGTx Holdings PLC MGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
-
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
-
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
-
Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
-
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
MeiraGTx Shares Rise Premarket on Ophthalmology Collaboration With Eli Lilly
Trading Information
- Previous Close Price
- $9.77
- Day Range
- $9.08–9.72
- 52-Week Range
- $6.62–15.35
- Bid/Ask
- $9.00 / $10.23
- Shares Outstanding
- 96.04M
- Market Cap
- $884.56M
- Volume/Avg
- 596,805 / 784,915
Key Statistics
- Price/Earnings (Normalized)
- 12.54
- Price/Sales
- 1.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 393
- Website
- https://www.meiragtx.com
Valuation
|
Metric
|
MGTX
|
|---|---|
Price/Earnings (Normalized) | 12.54 |
Price/Book Value | 4.02 |
Price/Sales | 1.96 |
Price/Cash Flow | 5.77 |
Price/Earnings
MGTX
Financial Strength
|
Metric
|
MGTX
|
|---|---|
Quick Ratio | 3.23 |
Current Ratio | 3.76 |
Interest Coverage | 7.41 |
Quick Ratio
MGTX
Profitability
|
Metric
|
MGTX
|
|---|---|
Return on Assets (Normalized) | 44.32% |
Return on Equity (Normalized) | 494.99% |
Return on Invested Capital (Normalized) | 108.56% |
Return on Assets
MGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>m^W&p | LOCK|&@Rcf | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|b!?KMG! | LOCK|S&@Y< | $83B | |||
| Moderna Inc
MRNA
| LOCK|QmhX!m | LOCK|^^l | $80B | |||
| argenx SE ADR
ARGX
| LOCK|Z!&kbV | LOCK|N<& | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<$X<jq | LOCK|#b | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|tF<hHT@ | LOCK|dj^x& | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|xBDtW<DD | LOCK|Fn?% | $28B | |||
| Incyte Corp
INCY
| LOCK|#L^TVH | LOCK|xCM | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|NGlzKm | LOCK|Gbh | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|qRSl%&$ | LOCK|SN$ | $14B |
United States